Oncobiologics Inc (NASDAQ:ONS) has been assigned an average broker rating score of 1.00 (Strong Buy) from the one analysts that cover the company, Zacks Investment Research reports. One investment analyst has rated the stock with a strong buy rating.
Analysts have set a 12-month consensus target price of $11.00 for the company, according to Zacks. Zacks has also assigned Oncobiologics an industry rank of 100 out of 265 based on the ratings given to its competitors.
Oncobiologics (NASDAQ ONS) traded down $0.01 on Wednesday, reaching $1.26. 97,479 shares of the company’s stock were exchanged, compared to its average volume of 142,091. The company has a debt-to-equity ratio of -0.01, a quick ratio of 0.03 and a current ratio of 0.03. Oncobiologics has a twelve month low of $0.78 and a twelve month high of $3.95.
A hedge fund recently raised its stake in Oncobiologics stock. Sabby Management LLC increased its position in shares of Oncobiologics Inc (NASDAQ:ONS) by 5.7% during the 2nd quarter, according to the company in its most recent 13F filing with the SEC. The firm owned 2,365,763 shares of the company’s stock after buying an additional 127,293 shares during the quarter. Sabby Management LLC owned about 9.59% of Oncobiologics worth $2,371,000 at the end of the most recent reporting period. Hedge funds and other institutional investors own 18.52% of the company’s stock.
Oncobiologics, Inc is a clinical-stage biopharmaceutical company. The Company is focused on identifying, developing, manufacturing and commercializing biosimilar therapeutics. It is focused on monoclonal antibodies (mAbs) in the disease areas of immunology and oncology. The Company offers BioSymphony Platform.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Oncobiologics Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Oncobiologics Inc and related companies with MarketBeat.com's FREE daily email newsletter.